U.S. buys more doses of Lilly’s COVID-19 treatment for $1.29 billion
U.S. buys more doses of Lilly’s COVID-19 treatment for $1.29 bln
November 2, 2021; 7:29 AM EDT
(Reuters) – Eli Lilly and Co (LLY.N) said on Tuesday that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion.
The U.S. Food and Drug Administration in September revised its emergency use authorization for the company’s cocktail, bamlanivimab and etesevimab, to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease. read more
Under the deal, Lilly will supply a minimum of 400,000 doses of its treatment by Dec. 31 and the rest by Jan. 31.
The new purchase is estimated to add $840 million to the company’s 2021 revenue forecast and about 25 cents of additional earnings per share, Lilly said.
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo
The U.S. government had bought 388,000 additional doses of Lilly’s antibody therapy in September, when infections surged due to the fast-spreading Delta variant read more
The treatment is also authorized for use in people 12 years and above with mild-to-moderate infection and at high risk for progression to severe COVID-19.
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
https://www.reuters.com/world/us/us-buys-more-doses-lillys-covid-19-treatment-129-bln-2021-11-02
